Future directions for peptide therapeutics development

Drug Discovery Today

Volumn 18, Issue 17-18, 2013, Pages 807-817

  Kaspar, Allan A ^a   Reichert, Janice M ^b  

^a PFIZER INC   (United States)

^b Reichert Biotechnology Consulting LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFAMELANOTIDE; ALBIGLUTIDE; ANTIDIABETIC AGENT; BLISIBIMOD; CARFILZOMIB; CILENGITIDE; CVX 096; DULAGLUTIDE; EXENDIN 4; GLATIRAMER; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GOSERELIN; GSK 2374697; LINACLOTIDE; LIRAGLUTIDE; LIXISENATIDE; LUCINACTANT; LUNG SURFACTANT; OCTREOTIDE; ORITAVANCIN; PARATHYROID HORMONE[1-34]; PASIREOTIDE; PEGINESATIDE; PEPTIDE; SEMAGLUTIDE; SUROTOMYCIN; TEDUGLUTIDE; TREBANANIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; URODILATIN;

ACROMEGALY; ACUTE HEART FAILURE; ADVANCED CANCER; ANEMIA; BREAST CANCER; CHEMOTHERAPY; CHRONIC DISEASE; CLINICAL STUDY; CLOSTRIDIUM DIFFICILE INFECTION; CONJUGATE; CONSTIPATION; CUSHING DISEASE; DIARRHEA; DRUG DEVELOPMENT; DRUG HALF LIFE; DRUG MARKETING; DRUG MECHANISM; ENDOMETRIOSIS; ERYTHROPOIETIC PROTOPORPHYRIA; GLIOBLASTOMA; HUMAN; IDIOPATHIC DISEASE; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPOROSIS; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREMATURITY; PROSTATE CANCER; RESPIRATORY DISTRESS SYNDROME; REVIEW; SHORT BOWEL SYNDROME; SKIN INFECTION; SYSTEMIC LUPUS ERYTHEMATOSUS; UTERINE TUBE DISEASE;

ANIMALS; DRUG APPROVAL; DRUG DISCOVERY; DRUGS, INVESTIGATIONAL; FORECASTING; HUMANS; MOLECULAR TARGETED THERAPY; PEPTIDES;

EID: 84883256420     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.05.011     Document Type: Review

References (49)

1. US Food and Drug Administration. Medical Review of NDA 202799. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2012/202799Orig1s000MedR. pdf
2. N. Svensen Peptides for cell-selective drug delivery Trends Pharmacol. Sci. 33 2012 186 192
3. F. Curnis Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells Cancer Res. 62 2002 867 874
4. L.R. Karaoui Oritavancin: an investigational lipoglycopeptide antibiotic Am. J. Health. Syst. Pharm. 70 2013 23 33
5. N. Shore, and B. Cowan The potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians Ther. Adv. Chronic Dis. 2 2011 377 383
6. J. Engel AEZS-108: a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors Expert Opin. Investig. Drugs 21 2012 891 899
7. A. Ben Jemaa Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies J. Exp. Clin. Cancer Res. 29 2010 171
8. S.R. Denmeade Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy Sci. Transl. Med. 4 140 2012 ra86
9. S.A. Williams A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease J. Natl. Cancer Inst. 99 2007 376 385
10. M. Lindgren, and U. Langel Classes and prediction of cell-penetrating peptides Methods Mol. Biol. 683 2011 3 19
11. S.K. Sha Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint Mol. Cancer Ther. 6 2007 147 153
12. Y. Matsumoto Screening of a library of T7 phage-displayed peptides identifies alphaC helix in 14-3-3 protein as a CBP501-binding site Bioorg. Med. Chem. 19 2011 7049 7056
13. J. Wang A peptide inhibitor of c-Jun N-terminal kinase protects against both aminoglycoside and acoustic trauma-induced auditory hair cell death and hearing loss J. Neurosci. 23 2003 8596 8607
14. M. Suckfuell Intratympanic treatment of acute acoustic trauma with a cell-permeable JNK ligand: a prospective randomized Phase I/II study Acta Otolaryngol. 127 2007 938 942
15. A.W. Hunter Zonula occludens-1 alters connexin43 gap junction size and organization by influencing channel accretion Mol. Biol. Cell 16 2005 5686 5698
16. P.M. McNeely Structure-function studies with G protein-coupled receptors as a paradigm for improving drug discovery and development of therapeutics Biotechnol. J. 7 2012 1451 1461
17. C. Koole Recent advances in understanding GLP-1R (glucagon-like peptide-1 receptor) function Biochem. Soc. Trans. 41 2013 172 179
18. F.S. Willard, and K.W. Sloop Physiology and emerging biochemistry of the glucagon-like peptide-1 receptor Exp. Diabetes Res. 2012 2012 470851
19. B. Kreymann Glucagon-like peptide-1 7-36: a physiological incretin in man Lancet 2 1987 1300 1304
20. European Medicines Agency. Exenatide Summary of Product Characteristics. Available at: www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product- Information/human/000698/WC500051845.pdf
21. A.H. Barnett Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes Core Evid. 6 2011 67 79
22. V.A. Fonseca Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono) Diabetes Care 35 2012 1225 1231
23. C. Thorkildsen Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice J. Pharmacol. Exp. Ther. 307 2003 490 496
24. H. Agersø The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men Diabetologia 45 2002 195 202
25. US Food and Drug Administration Center for Drug Evaluation and Research. Liraglutide Summary Basis for Regulatory Action. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2010/022341s000sumr.pdf
26. J.T. Andersen Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor Nat. Commun. 3 2012 610
27. R. Jefferis Isotype and glycoform selection for antibody therapeutics Arch. Biochem. Biophys. 526 2012 159 166
28. J.E. Matthews Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes J. Clin. Endocrinol. Metab. 93 2008 4810 4817
29. W. Glaesner Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein Diabetes Metab. Res. Rev. 26 2010 287 296
30. P. Barrington A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes Diabetes Obes. Metab. 13 2011 426 433
31. Nauck, M.A. et al. (2012) The once-weekly human GLP-1 analogue semaglutide provides significant reductions in HbA1c and body weight in patients with type 2 diabetes. 48th European Association for the Study of Diabetes Annual Meeting (Abstr. 2). Available at: http:// novonordiskscientificmaterial2012.com/EASD/Presentations/2.pdf
32. Kapitza, C. et al. (2012) Safety, tolerability, pharmacokinetics (PK)/pharmacodynamics (PD) of single escalating doses of semaglutide, a unique once weekly GLP-1 analogue, in healthy male subjects. 48th European Association for the Study of Diabetes Annual Meeting (Abstr. 826). Available at: http://novonordiskscientificmaterial2012.com/EASD/Presentations/826.pdf
33. Y.M. Cho Targeting the glucagon receptor family for diabetes and obesity therapy Pharmacol. Ther. 135 2012 247 278
34. A. Astrup Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study Lancet 374 2009 1606 1616
35. A. Astrup Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide Int. J. Obes. (Lond.) 36 2012 843 854
36. D.J. Drucker Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits Diabetes Care 33 2010 428 433
37. D. Mundil GLP-1 receptor agonists: a clinical perspective on cardiovascular effects Diab. Vasc. Dis. Res. 9 2012 95 108
38. D. Lorber GLP-1 receptor agonists: effects on cardiovascular risk reduction Cardiovasc. Ther. 2013 10.1111/1755-5922.12000 (in press)
39. R.S. McIntyre The neuroprotective effects of GLP-1: possible treatments for cognitive deficits in individuals with mood disorders Behav. Brain Res. 237 2013 164 171
40. C. Hölscher Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease Biochem. Soc. Trans. 39 2011 891 897
41. J.M. Reichert Bispecific antibodies and ADCs: once and future kings? MAbs 3 2011 329 330
42. I. Rentero Rebollo, and C. Heinis Phage selection of bicyclic peptides Methods 60 2013 46 54
43. A. Angelini Chemical macrocyclization of peptides fused to antibody Fc fragments Bioconjug. Chem. 23 2012 1856 1863
44. A. Angelini Bicyclization and tethering to albumin yields long-acting peptide antagonists J. Med. Chem. 55 2012 10187 10197
45. L.K. Henchey Contemporary strategies for the stabilization of peptides in the alpha-helical conformation Curr. Opin. Chem. Biol. 12 2008 692 697
46. Z. Guo Probing the alpha-helical structural stability of stapled p53 peptides: molecular dynamics simulations and analysis Chem. Biol. Drug Des. 75 2010 348 359
47. T.K. Sawyer AILERON therapeutics Chem. Biol. Drug Des 73 2009 3 6
48. G.H. Bird Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic Proc. Natl. Acad. Sci. U. S. A. 107 2010 14093 14098
49. Y. Chang ATSP-7041, a dual MDM2 and MDMX targeting stapled α-helical peptide exhibits potent in vitro and in vivo efficacy in xenograft models of human cancer 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2012 Abstr. 226